首页> 外文期刊>International heart journal >Effects of Three Month Nasal Continuous Positive Airway Pressure Treatment on Electrocardiographic, Echocardiographic and Overnight Polysomnographic Parameters in Newly Diagnosed Moderate/Severe Obstructive Sleep Apnea Patients
【24h】

Effects of Three Month Nasal Continuous Positive Airway Pressure Treatment on Electrocardiographic, Echocardiographic and Overnight Polysomnographic Parameters in Newly Diagnosed Moderate/Severe Obstructive Sleep Apnea Patients

机译:新近诊断为中度/重度阻塞性睡眠呼吸暂停患者的连续三个月鼻气道正压通气治疗对心电图,超声心动图和夜间多导睡眠图参数的影响

获取原文
           

摘要

The objective of the study was to determine the effects of nasal continuous positive airway pressure (nCPAP) therapy on left ventricular (LV) function and electrocardiographic parameters in newly diagnosed moderate/severe obstructive sleep apnea (OSA) patients without cardiovascular comorbidities and medical treatments. We examined 44 patients who underwent overnight polysomnography together with 24-hour Holter electrocardiography, cardiopulmonary exercise testing including heart rate recovery at 1 minute (HRR-1), echocardiography, surface electrocardiography, and those who were diagnosed with moderate/severe OSA apnea—hypopnea index ≥ 15. After 3 months of nCPAP treatment, the above-mentioned examinations were repeated. Forty-four patients completed the treatment period. Twelve weeks on effective nCPAP induced a significant increase in the mitral E/A ratio ( P = 0.001), as well as reductions in isovolumic relaxation time ( P = 0.001) and mitral deceleration time (DT) ( P = 0.002). There were no significant differences in LV ejection fraction, LV mass index, and pulsed wave Doppler parameters. Mean heart rate was 79.2 ± 12.5 pulses/minute, maximum P-wave duration 117.5 ± 8.6 msec, P-wave dispersion (PWd) 54.6 ± 10.2 msec, corrected QT interval (QTc) 436.5 ± 40.5 msec, and QT dispersion (QTd) 46.3 ± 7.1 msec, which significantly decreased to 70.4 ± 9.6 pulses/minute ( P < 0.001), 111.5 ± 8.7 msec ( P < 0.001), 51.6 ± 8.9 msec ( P < 0.001), 418.4 ± 31.2 msec ( P < 0.001), and 33.8 ± 3.4 msec ( P < 0.001), respectively. Exercise capacity at baseline determined as 10.5 ± 2.2 metabolic equivalents (METS) and HRR-1 (20.6 ± 11.7 bpm) significantly increased (12.1 ±1.5 METS and 27.4 ± 8.6 bpm). There was no significant difference in aortic root parameters. Three-month nCPAP therapy significantly increased LV shortening fraction, with no effect on systolic function or aortic root diameters and a positive effect on heart rate, PWd, HRR-1, QTc and QTd time following nCPAP therapy.
机译:这项研究的目的是确定在没有心血管合并症和药物治疗的新诊断的中度/重度阻塞性睡眠呼吸暂停(OSA)患者中,鼻持续气道正压通气(nCPAP)治疗对左心室(LV)功能和心电图参数的影响。我们检查了44例接受通宵多导睡眠监测,24小时动态心电图检查,心肺运动测试(包括1分钟心率恢复(HRR-1)),超声心动图,表面心电图检查的患者,以及诊断为中度/重度OSA呼吸暂停-呼吸不足的患者指数≥15。nCPAP治疗3个月后,重复上述检查。四十四名患者完成了治疗期。有效nCPAP治疗12周后,二尖瓣E / A比明显增加(P = 0.001),等容舒张时间(P = 0.001)和二尖瓣减速时间(DT)减少(P = 0.002)。左室射血分数,左室质量指数和脉冲多普勒参数无明显差异。平均心率是79.2±12.5脉冲/分钟,最大P波持续时间117.5±8.6毫秒,P波离散度(PWd)54.6±10.2毫秒,校正后的QT间隔(QTc)436.5±40.5毫秒,以及QT离散度(QTd) 46.3±7.1毫秒,显着下降至70.4±9.6脉冲/分钟(P <0.001),111.5±8.7毫秒(P <0.001),51.6±8.9毫秒(P <0.001),418.4±31.2毫秒(P <0.001)和33.8±3.4毫秒(P <0.001)。基线时的运动能力确定为10.5±2.2代谢当量(METS)和HRR-1(20.6±11.7 bpm)显着增加(12.1±1.5 METS和27.4±8.6 bpm)。主动脉根部参数无明显差异。为期三个月的nCPAP治疗显着增加了LV缩短率,对收缩功能或主动脉根部直径无影响,对nCPAP治疗后的心率,PWd,HRR-1,QTc和QTd时间有积极影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号